Morning Overview on MSN
Eli Lilly’s new Zepbound pen packs a full month of obesity doses
Eli Lilly and Company (NYSE: LLY) announced on February 23, 2026, that the U.S. Food and Drug Administration has approved a ...
Consolidation of four doses may lower secondary packaging complexity and improve fill-finish throughput predictability, although Lilly has not quantified manufacturing efficiency gains. Multi-dose use ...
Eli Lilly, the drugmaker behind weight-loss treatments Mounjaro and Zepbound, has rapidly overtaken former market leader Novo ...
Eli Lilly has rolled out a multi-dose KwikPen version of tirzepatide, marketed as Zepbound, for chronic weight management—signaling a packaging update for one of the obesity market’s fastest-expanding ...
Packaging Gateway on MSN
Swisslog Healthcare introduces Motif Tabletop packager
Motif is equipped with LED-lighted cells to assist with medication placement, and its print layouts.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results